查看购物车
  • Traditional Chinese
  • English
  • Japanese
2031年亚太地区青光眼治疗市场预测 - 区域分析 - 按药物类别、适应症和配销通路
市场调查报告书
商品编码
1764892

2031年亚太地区青光眼治疗市场预测 - 区域分析 - 按药物类别、适应症和配销通路

Asia Pacific Glaucoma Therapeutics Market Forecast to 2031 - Regional Analysis - by Drug Class, Indication, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 137 Pages | 订单完成后即时交付

价格

2023 年亚太青光眼治疗市场价值为 12.118 亿美元，预计到 2031 年将达到 15.9841 亿美元；预计 2023 年至 2031 年的复合年增长率为 3.5%。

穿戴式科技的发展推动亚太青光眼治疗市场

技术创新一直是任何生命科学学科（包括眼科学）的基础，因为现代设备是准确诊断和改进治疗的关键。治疗方法的进步使得青光眼的治疗得到改善。穿戴式青光眼诊断和治疗产品已成为潜在的解决方案。传统诊断技术提供可靠的眼压资料，而 Sensimed Triggerfish 等创新隐形眼镜则提供持续的眼压追踪。先进的药物洗脱隐形眼镜也正在成为青光眼治疗的潜在解决方案。 2023 年 3 月，SpyGlass Pharma 发布了其首次人体青光眼治疗试验的 6 个月资料。资料显示，其新的药物输送平台（一种带有药物洗脱垫的一体式疏水性丙烯酸人工水晶体）继续显着降低患有青光眼或眼高压患者的眼压。因此，此类现代穿戴式产品的开发可能会在未来几年推动对青光眼治疗的需求。

亚太青光眼治疗市场概况

亚太地区的青光眼治疗市场细分为中国、日本、印度、澳洲、韩国和亚太其他地区。该地区市场的成长归因于青光眼发病率的上升、老年人口的增加以及促进研究活动的投资激增。主要市场参与者正在采取合併、收购、产品发布和融资等策略来扩大其市场份额。 2023 年 2 月，兆科眼科的比马前列素噻吗洛尔滴眼液获得国家药品监督管理局 (NMPA) 的上市许可，用于治疗青光眼。 2023 年 2 月，参天製药股份有限公司的 STN1011101 滴眼液申请获得了 NMPA 的上市许可。这款不含防腐剂的配方含有 0.0015% 的他氟前列素和 0.5% 的噻吗洛尔，由参天製药和 AGC Inc. 共同开发。该药物旨在满足中国青光眼治疗中尚未满足的需求。

2022年2月发表在《BMC眼科期刊》的研究报告显示，中国是全球青光眼发生率最高的国家。此外，2020年，中国各类青光眼患者人数达1,558万人，预计2050年将激增至2,516万人。青光眼的高发生率预计将在未来推动该疾病治疗药物的成长。中国青光眼治疗市场的成长主要归功于市场参与者采取的各种成长策略以及人口老化的加剧。

亚太青光眼治疗市场收入及预测（2031年）（百万美元）

亚太青光眼治疗市场区隔

亚太青光眼治疗市场按药物类别、适应症、配销通路和国家分类。

依药物类别，亚太地区青光眼治疗市场细分为β受体阻断剂、α肾上腺素激动剂、前列腺素类似物、碳酸酐酶抑制剂、复方药物及其他。前列腺素类似物在2023年占据了最大的市场。

依适应症划分，亚太地区青光眼治疗市场分为开角型青光眼、闭角型青光眼及其他类型。 2023年，开角型青光眼占了最大的市场。

按配销通路划分，亚太地区青光眼治疗市场分为医院药房、零售药房和线上药房。 2023年，医院药局占了最大的市场份额。

按国家/地区划分，亚太地区青光眼治疗市场分为中国、日本、印度、澳洲、韩国和亚太其他地区。 2023年，中国占据亚太地区青光眼治疗市场的主导地位。

Alcon AG、AbbVie Inc、Bausch & Lomb Inc, LLC、Viatris Inc、Novartis AG、Sun Pharmaceutical Industries Ltd、Teva Pharmaceuticals Industries Ltd、Thea Pharma Inc 和 Santen Pharmaceutical Co., Ltd. 是亚太地区青光眼治疗市场领先的公司。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：亚太青光眼治疗市场－关键市场动态

  • 青光眼治疗市场－关键市场动态
  • 市场驱动因素
    • 青光眼发生率不断上升
    • 产品发布、合作和收购的数量不断增加
  • 市场限制
    • 药物治疗方案依从性问题
  • 市场机会
    • 穿戴式科技的发展
  • 未来趋势
    • 新型药物输送方法的开发
  • 驱动因素和限制因素的影响：

第五章：青光眼治疗市场－亚太地区分析

  • 2021-2031年青光眼治疗市场收入
  • 青光眼治疗市场预测分析

第六章：亚太地区青光眼治疗市场分析－依药物类别

  • β受体阻断剂
  • α肾上腺素激动剂
  • 前列腺素类似物
  • 碳酸酐酶抑制剂
  • 联合用药
  • 其他的

第七章：亚太地区青光眼治疗市场分析－按适应症

  • 开角型青光眼
  • 闭角型青光眼
  • 其他的

第八章：亚太地区青光眼治疗市场分析－按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第九章：亚太青光眼治疗市场—国家分析

    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳洲
      • 韩国
      • 亚太地区其他地区

第 10 章：青光眼治疗市场-产业格局

  • 青光眼治疗市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第 11 章：公司简介

  • Alcon AG
  • AbbVie Inc
  • Bausch & Lomb Inc
  • Viatris Inc
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Thea Pharma Inc
  • Santen Pharmaceutical Co., Ltd.

第 12 章：附录

Product Code: BMIRE00031612

The Asia Pacific glaucoma therapeutics market was valued at US$ 1,211.80 million in 2023 and is expected to reach US$ 1,598.41 million by 2031; it is estimated to register a CAGR of 3.5% from 2023 to 2031.

Development of Wearable Technologies Fuels Asia Pacific Glaucoma Therapeutics Market

Technological innovation has always been fundamental to any discipline of life sciences, including ophthalmology, as modern devices are key to accurate diagnosis and improved treatments. Advancements in treatments have enabled the improved treatment of glaucoma. Wearable glaucoma diagnostics and therapeutics products have emerged as potential solutions. Conventional diagnostic techniques provide reliable intraocular pressure data, while innovative contact lenses such as Sensimed Triggerfish offer continuous IOP tracking. Advanced drug-eluting contact lenses are also emerging as a potential solution for glaucoma therapy. In March 2023, SpyGlass Pharma released 6-month data from its first-in-human glaucoma treatment trial. The data shows that its new drug delivery platform, which is a single-piece, hydrophobic acrylic intraocular lens with drug-eluting pads, continues to significantly lower IOP in patients suffering from glaucoma or ocular hypertension. Thus, the development of such modern wearable products is likely to propel the demand for glaucoma therapeutics in the coming years.

Asia Pacific Glaucoma Therapeutics Market Overview

The glaucoma therapeutics market in Asia Pacific is subsegmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Market growth in this region is ascribed to the rising incidence of glaucoma, the growing geriatric population, and surging investments to boost research activities. Key market players are adopting strategies such as mergers, acquisitions, product launches, and fundraising to expand their market presence. In February 2023, Zhaoke Ophthalmology's Bimatoprost Timolol eye drops received marketing authorization from the National Medical Products Administration (NMPA) for their use in glaucoma treatment. In February 2023, Santen Pharmaceutical Co., Ltd. received the marketing authorization from the NMPA for its application for STN1011101 eye drops. This preservative-free formulation containing tafluprost 0.0015% and timolol 0.5% was codeveloped by Santen and AGC Inc. The drug aims to address the unmet needs for glaucoma treatment in China.

A study published in the BMC Ophthalmology Journal in February 2022 reported that China has the highest rate of glaucoma in the world. Moreover, the country had 15.58 million people with all types of glaucoma in 2020, and the number is projected to spike up to 25.16 million by 2050. The high prevalence of glaucoma is expected to drive the growth of therapeutics to manage the disease in the future. The glaucoma therapeutics market growth in China is primarily attributed to various growth strategies adopted by market players and the increasing aging population.

Asia Pacific Glaucoma Therapeutics Market Revenue and Forecast to 2031 (US$ Million)

Asia Pacific Glaucoma Therapeutics Market Segmentation

The Asia Pacific glaucoma therapeutics market is categorized into drug class, indication, distribution channel, and country.

Based on drug class, the Asia Pacific glaucoma therapeutics market is segmented into beta blockers, alpha adrenergic agonists, prostaglandins analogues, carbonic anhydrase inhibitors, combination drugs, and others. The prostaglandins analogues segment held the largest market share in 2023.

In terms of indication, the Asia Pacific glaucoma therapeutics market is categorized into open angle glaucoma, angle closure glaucoma, and others. The open angle glaucoma segment held the largest market share in 2023.

By distribution channel, the Asia Pacific glaucoma therapeutics market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment held the largest market share in 2023.

By country, the Asia Pacific glaucoma therapeutics market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific glaucoma therapeutics market share in 2023.

Alcon AG, AbbVie Inc, Bausch & Lomb Inc, LLC, Viatris Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals Industries Ltd, Thea Pharma Inc, and Santen Pharmaceutical Co., Ltd. are among the leading companies operating in the Asia Pacific glaucoma therapeutics market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Asia Pacific Glaucoma Therapeutics Market - Key Market Dynamics

  • 4.1 Glaucoma Therapeutics Market - Key Market Dynamics
  • 4.2 Market Drivers
    • 4.2.1 Mounting Incidence of Glaucoma Disease
    • 4.2.2 Increasing Number of Product Launches, Collaborations, and Acquisitions
  • 4.3 Market Restraints
    • 4.3.1 Medication Regimen Compliance Issues
  • 4.4 Market Opportunities
    • 4.4.1 Development of Wearable Technologies
  • 4.5 Future Trends
    • 4.5.1 Development of Novel Drug Delivery Methods
  • 4.6 Impact of Drivers and Restraints:

5. Glaucoma Therapeutics Market - Asia Pacific Analysis

  • 5.1 Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • 5.2 Glaucoma Therapeutics Market Forecast Analysis

6. Asia Pacific Glaucoma Therapeutics Market Analysis - by Drug Class

  • 6.1 Beta Blockers
    • 6.1.1 Overview
    • 6.1.2 Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.2 Alpha Adrenergic Agonists
    • 6.2.1 Overview
    • 6.2.2 Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.3 Prostaglandins Analogues
    • 6.3.1 Overview
    • 6.3.2 Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Overview
    • 6.4.2 Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.5 Combination Drugs
    • 6.5.1 Overview
    • 6.5.2 Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 6.6 Others
    • 6.6.1 Overview
    • 6.6.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

7. Asia Pacific Glaucoma Therapeutics Market Analysis - by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Overview
    • 7.1.2 Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Overview
    • 7.2.2 Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Others
    • 7.3.1 Overview
    • 7.3.2 Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

8. Asia Pacific Glaucoma Therapeutics Market Analysis - by Distribution Channel

  • 8.1 Hospital Pharmacy
    • 8.1.1 Overview
    • 8.1.2 Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Retail Pharmacy
    • 8.2.1 Overview
    • 8.2.2 Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Online Pharmacy
    • 8.3.1 Overview
    • 8.3.2 Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)

9. Asia Pacific Glaucoma Therapeutics Market - Country Analysis

  • 9.1 Asia Pacific Glaucoma Therapeutics Market Overview
    • 9.1.1 Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Key Country, 2023 and 2031 (%)
      • 9.1.1.1 Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast Analysis - by Country
      • 9.1.1.2 China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.2.1 China: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.2.2 China: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.2.3 China: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.3 Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.3.1 Japan: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.3.2 Japan: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.3.3 Japan: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.4 India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.4.1 India: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.4.2 India: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.4.3 India: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.5 Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.5.1 Australia: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.5.2 Australia: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.5.3 Australia: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.6 South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.6.1 South Korea: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.6.2 South Korea: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.6.3 South Korea: Glaucoma Therapeutics Market Breakdown, by Distribution Channel
      • 9.1.1.7 Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
        • 9.1.1.7.1 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Drug Class
        • 9.1.1.7.2 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Indication
        • 9.1.1.7.3 Rest of APAC: Glaucoma Therapeutics Market Breakdown, by Distribution Channel

10. Glaucoma Therapeutics Market - Industry Landscape

  • 10.1 Growth Strategies in Glaucoma Therapeutics Market
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Alcon AG
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Bausch & Lomb Inc
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Viatris Inc
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Novartis AG
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Sun Pharmaceutical Industries Ltd
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Teva Pharmaceutical Industries Ltd
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Thea Pharma Inc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Santen Pharmaceutical Co., Ltd.
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms

List Of Tables

  • Table 1. Asia Pacific Glaucoma Therapeutics Market Segmentation
  • Table 2. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Table 3. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 4. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 5. Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 6. Asia Pacific: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Country
  • Table 7. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 8. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 9. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 10. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 11. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 12. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 13. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 14. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 15. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 16. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 17. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 18. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 19. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 20. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 21. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 22. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Class
  • Table 23. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Indication
  • Table 24. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million) - by Distribution Channel
  • Table 25. Recent Organic Growth Strategies in Glaucoma Therapeutics Market
  • Table 26. Recent Inorganic Growth Strategies in the Glaucoma Therapeutics Market
  • Table 27. Glossary of Terms

List Of Figures

  • Figure 1. Asia Pacific Glaucoma Therapeutics Market Segmentation, by Country
  • Figure 2. Impact Analysis of Drivers and Restraints
  • Figure 3. Glaucoma Therapeutics Market Revenue (US$ Million), 2021-2031
  • Figure 4. Glaucoma Therapeutics Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 5. Beta Blockers: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 6. Alpha Adrenergic Agonists: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 7. Prostaglandins Analogues: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Carbonic Anhydrase Inhibitors: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Combination Drugs: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Glaucoma Therapeutics Market Share (%) - by Indication (2023 and 2031)
  • Figure 12. Open Angle Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. Angle Closure Glaucoma: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 14. Others: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Glaucoma Therapeutics Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 16. Hospital Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Retail Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Online Pharmacy: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Asia Pacific Glaucoma Therapeutics Market, by Key Country - Revenue (2023) (US$ Million)
  • Figure 20. Asia Pacific: Glaucoma Therapeutics Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 21. China: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Japan: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. India: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 24. Australia: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. South Korea: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Rest of APAC: Glaucoma Therapeutics Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. Growth Strategies in Glaucoma Therapeutics Market